aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАНateroskleroz-46Research ArticleОБЗОРЫREVIEWSПРИМЕНЕНИЕ ВНУТРИВЕННЫХ ФОРМ БЕТА-АДРЕНОБЛОКАТОРОВ ПРИ ОСТРОМ КОРОНАРНОМ СИНДРОМЕTHE USE OF INTRAVENOUS FORMS OF BETA-BLOCKERS IN ACUTE CORONARY SYNDROMEАстраханцеваИ. Д.AstrakhantsevaI. D.astrakirina@yandex.ruУрванцеваИ. А.UrvantsevaI. A.noemail@neicon.ruНиколаевК. Ю.NikolaevK. Yu.noemail@neicon.ruБУ ХМАО-Югры Окружной кардиологический диспансер «Центр диагностики и сердечно-сосудистой хирургии»State-Financed Organization Khanty-Mansi Autonomous Region - Ugra District Cardiodispensary «Centre of Diagnosis and Cardiovascular Surgery»ФГБНУ НИИ терапии и профилактической медициныInstitute of Internal and Preventive Medicine2017270920191325054Copyright © Астраханцева И.Д., Урванцева И.А., Николаев К.Ю., 20192019Астраханцева И.Д., Урванцева И.А., Николаев К.Ю.Astrakhantseva I.D., Urvantseva I.A., Nikolaev K.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/46

Бета-блокаторы активно используются в лечении пациентов с хронической и острой ишемической болезнью. На протяжении всего периода изучения эффектов бета-блокаторов при остром инфаркте миокарда (ОИМ) клинические исследования проводились в условиях фармакологической реперфузии коронарных артерий; при этом данные о клинической эффективности бета-блокаторов у пациентов при инвазивной стратегии лечения ОИМ в международной литературе ограничены. Целью настоящего обзора является анализ данных мировой литературы по применению инъекционных форм бета-адреноблокаторов при остром коронарном синдроме. На основании данных анализа сделан вывод, что внутривенное введение метопролола в острый период инфаркта миокарда отчетливо приводит к ограничению зоны некроза, снижает риск повторного инфаркта миокарда и уменьшает частоту развития фибрилляции желудочков.

Beta- blockers are actively used in the treatment of patients with chronic and acute ischemic heart disease. Throughout the study period of effects of beta-blockers to limit myocardial necrosis at acute myocardial infarction (AMI) clinical researches were performed under pharmacological reperfusion of the coronary arteries; herewith the data about the clinical efficacy of beta-blockers of the patients with invasive strategy treatment of AMI are limited in international literature. The purpose of this review is to analyze the world literature on the use of injection forms of beta-blockers in acute coronary syndrome. Based on the analysis, it was concluded that the intravenous administration of metoprolol in the acute period of myocardial infarction clearly leads to the restriction of the necrosis zone, reduces the risk of repeated myocardial infarction and reduces the incidence of ventricular fibrillation.

острый инфаркт миокардавнутривенная форма бета-блокаторовметопрололacute myocardial infarctionintravenous beta-blockersmetoprololReferencesFrishman W.H. Beta-adrenergic blocking drugs // Am. Coll. Cardiol. Curr. J. Rev. 1997. Vol. 23.Frishman W.H. Beta-adrenergic blocking drugs // Am. Coll. Cardiol. Curr. J. Rev. 1997. Vol. 23.Kaumann A.J. Some aspects of heart beta-adrenoceptor function // Cardiovasc. Drugs. Ther. 1991. Vol. 5. P. 549Kaumann A.J. Some aspects of heart beta-adrenoceptor function // Cardiovasc. Drugs. Ther. 1991. Vol. 5. P. 549Motomura S., Zerkowski H.R., Daul A. et al. On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies // Am. Heart J. 1990. Vol. 119. P. 608.Motomura S., Zerkowski H.R., Daul A. et al. On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies // Am. Heart J. 1990. Vol. 119. P. 608.Gong H. et al. Specific beta2 AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta 2 AR in myocytes from failing human heart // Circulation. 2002. Vol. 105. P. 2497-2503.Gong H. et al. Specific beta2 AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta 2 AR in myocytes from failing human heart // Circulation. 2002. Vol. 105. P. 2497-2503.Cruickshank J.M., Prichard B.N.C. Beta-adrenoceptors // Beta-blockers in clinical practice. London: Churchill Livingstone, 1996. P. 9-86.Cruickshank J.M., Prichard B.N.C. Beta-adrenoceptors // Beta-blockers in clinical practice. London: Churchill Livingstone, 1996. P. 9-86.Lopez-Sendon J., Swedberg K., McMurray J. et al. Expert consensus document on β-adrenergic receptor blockers. The Task Force on Beta Blockers of the European Society of Cardiology // Eur. Heart J. 2004. Vol. 25. P. 1341-1362.Lopez-Sendon J., Swedberg K., McMurray J. et al. Expert consensus document on β-adrenergic receptor blockers. The Task Force on Beta Blockers of the European Society of Cardiology // Eur. Heart J. 2004. Vol. 25. P. 1341-1362.Ярохно Н.Н., Бондарева З.Г., Николаев К.Ю. Острый инфаркт миокарда: новые возможности ранней диагностики, лечения и прогноза. Новосибирск: Сибмедиздат НГМУ, 2011. 200 с.Ярохно Н.Н., Бондарева З.Г., Николаев К.Ю. Острый инфаркт миокарда: новые возможности ранней диагностики, лечения и прогноза. Новосибирск: Сибмедиздат НГМУ, 2011. 200 с.The Norwegian Multicenter Study Grooup. Timolol-induced reduction in mortality and reinfarction inpatients surviving acute myocardial infarction // N. Engl. J. Med. 1981. Vol. 304. P. 801-807.The Norwegian Multicenter Study Grooup. Timolol-induced reduction in mortality and reinfarction inpatients surviving acute myocardial infarction // N. Engl. J. Med. 1981. Vol. 304. P. 801-807.Beta-Blocker Heart Attack Trial Reseach Group. A randomized trial of propranoloi in patients with acute myocardial infarction. L Mortality results // JAMA. 1982. Vol. 247. P. 1707-1714.Beta-Blocker Heart Attack Trial Reseach Group. A randomized trial of propranoloi in patients with acute myocardial infarction. L Mortality results // JAMA. 1982. Vol. 247. P. 1707-1714.Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blocade on mortality among high-risk and low-risk patients after myocardial infarction // N. Engl. J. Med. 1998. Vol. 339. P. 489-497.Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blocade on mortality among high-risk and low-risk patients after myocardial infarction // N. Engl. J. Med. 1998. Vol. 339. P. 489-497.First International Study of Infarct Survival Collaborative Group Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1 // Lancet. 1986. Vol. 2. P. 57-66.First International Study of Infarct Survival Collaborative Group Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1 // Lancet. 1986. Vol. 2. P. 57-66.Hjalmarson A., Elmfeldt D., Herlitz J. et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blindrandomisedtrial // Lancet. 1981. Vol. 2. P. 823-827.Hjalmarson A., Elmfeldt D., Herlitz J. et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blindrandomisedtrial // Lancet. 1981. Vol. 2. P. 823-827.Norris R.M., Barnaby P.F., Brown M.A. et al. Prevention of ventricularfibrillation during acute myocardial infarction by intravenous pro-pranolol // Lancet. 1984. Vol. 2. P. 883-886.Norris R.M., Barnaby P.F., Brown M.A. et al. Prevention of ventricularfibrillation during acute myocardial infarction by intravenous pro-pranolol // Lancet. 1984. Vol. 2. P. 883-886.Chen Z.M., Pan H.C., Chen Y.P. et al. Early intravenous than oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial // Lancet. 2005. Vol. 366. P. 1622-1632.Chen Z.M., Pan H.C., Chen Y.P. et al. Early intravenous than oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial // Lancet. 2005. Vol. 366. P. 1622-1632.Vande Werf F., Bax J., Betriu A. et al. Management of acutemyocardial infarction in patients presenting with persistent ST-segment elevation:The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology // Eur. Heart J. 2008. Vol. 29. P. 2909-2945.Vande Werf F., Bax J., Betriu A. et al. Management of acutemyocardial infarction in patients presenting with persistent ST-segment elevation:The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology // Eur. Heart J. 2008. Vol. 29. P. 2909-2945.Antman E.M., Hand M., Armstrong P.W. et al. 2007 focusedupdate of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol. 2008. Vol. 51. P. 210-247.Antman E.M., Hand M., Armstrong P.W. et al. 2007 focusedupdate of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol. 2008. Vol. 51. P. 210-247.The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled international trial // Eur. Heart J. 1985. Vol. 6. P. 199-226.The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled international trial // Eur. Heart J. 1985. Vol. 6. P. 199-226.Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1 (First International Study of Infarct Survival) Collaborative Group // Lancet. 1986. Vol. 2. P. 57-66.Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1 (First International Study of Infarct Survival) Collaborative Group // Lancet. 1986. Vol. 2. P. 57-66.Roberts R., Rogers W.J., Mueller H.S. et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study // Circulation. 1991. Vol. 83. P. 422-437.Roberts R., Rogers W.J., Mueller H.S. et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study // Circulation. 1991. Vol. 83. P. 422-437.Pfisterer M., Cox J.L., Granger C.B., et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA Alteplase) for Occluded Coronary Arteries // J. Am. Coll. Cardiol. 1988. Vol. 32. P. 634-640.Pfisterer M., Cox J.L., Granger C.B., et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA Alteplase) for Occluded Coronary Arteries // J. Am. Coll. Cardiol. 1988. Vol. 32. P. 634-640.Prasad A., Stone G.W., Aymong E. et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial // Am. Heart J. 2004. Vol. 147. P. 669-675.Prasad A., Stone G.W., Aymong E. et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial // Am. Heart J. 2004. Vol. 147. P. 669-675.Halkin A., Grines C.L., Cox D.A. et al. Impact of intravenous beta-blockade before primary angio- plasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction // J. Am. Coll. Cardiol. 2004. Vol. 43. P. 1780-1787.Halkin A., Grines C.L., Cox D.A. et al. Impact of intravenous beta-blockade before primary angio- plasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction // J. Am. Coll. Cardiol. 2004. Vol. 43. P. 1780-1787.Valle J.A., Zhang M., Dixon S. et al. Impact of pre-procedural beta-blockade on inpatient mortality in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction // Am. J. Cardiol. 2013. Vol. 111. P. 1714-1720.Valle J.A., Zhang M., Dixon S. et al. Impact of pre-procedural beta-blockade on inpatient mortality in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction // Am. J. Cardiol. 2013. Vol. 111. P. 1714-1720.Sharma S.K., Kini A., Marmur J.D., Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival // Circulation. 2000. Vol. 102. P. 166-172.Sharma S.K., Kini A., Marmur J.D., Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival // Circulation. 2000. Vol. 102. P. 166-172.Ellis S.G., Brener S.J., Lincoff A.M. et al. Beta-blockers before percutaneous coronary intervention do not attenuate postproceduralcreatine kinase isoenzyme rise // Circulation. 2001. Vol. 104. P. 2685-2688.Ellis S.G., Brener S.J., Lincoff A.M. et al. Beta-blockers before percutaneous coronary intervention do not attenuate postproceduralcreatine kinase isoenzyme rise // Circulation. 2001. Vol. 104. P. 2685-2688.Ibanez B., Cimmino G., Prat-González S. et al. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion // Int. J. Cardiol. 2011. Vol. 147. P. 428-432.Ibanez B., Cimmino G., Prat-González S. et al. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion // Int. J. Cardiol. 2011. Vol. 147. P. 428-432.Ndrepepa G., Kastrati A. Intravenous Β-Blockers in Primary Percutaneous Coronary Intervention: New Hope for an Old Therapy // Circulation. 2013. Vol. 128. P. 1487-1489.Ndrepepa G., Kastrati A. Intravenous Β-Blockers in Primary Percutaneous Coronary Intervention: New Hope for an Old Therapy // Circulation. 2013. Vol. 128. P. 1487-1489.Ibanez B., Macaya C., Sánchez-Brunete V. et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial // Circulation. 2013. Vol. 128. P. 1495-1503.Ibanez B., Macaya C., Sánchez-Brunete V. et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial // Circulation. 2013. Vol. 128. P. 1495-1503.

The authors declare that there are no conflicts of interest present.